However, Dhanesha and colleagues have demonstrated that NAFLD can be reduced in db/db mice if a glucokinase agonist is co-administered with exendin-4, a GLP-1 agonist [28]. The gene discussed is GCK; the disease is metabolic dysfunction-associated steatotic liver disease.